Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

BioTime Inks Progenitor Cell Distribution Deal for China

publication date: Dec 9, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
BioTime of California has signed up Shanghai Genext Medical Technology as the China marketer of its ACTCellerate™ cell lines, a highly purified source of progenitor cells. Genext will also sell BioTime’s cell cultures, which are customized for each line. ACTCellerate™ is BioTime’s proprietary technology that allows the expansion of over 140 highly-purified primitive human embryonic progenitor cells (hEPCs) from hES or induced pluripotent stem (iPS) cells. More details....

Stock Symbol: (NYSE Amex: BTX)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners